

FOR IMMEDIATE RELEASE

January 9, 2025

Cionic Appoints MedTech Veteran Brooke Harding as Chief Commercial Officer, Marking Next Phase of Growth



San Francisco, CA — [Cionic](#), the pioneering company behind the first FDA-cleared wearable neurotechnology for, today announced the appointment of Brooke Harding as Chief Commercial Officer. Harding brings more than two decades of experience in medtech and digital health, joining Cionic as the company accelerates its mission to lead the future of walking by powering human movement through its groundbreaking Neural Sleeve.

“Brooke’s leadership and track record of building high-performing, purpose-driven organizations will be invaluable as we enter this next exciting chapter,” said Jeremiah Robison, founder and CEO of Cionic. “With the recent launch of our second-generation Neural Sleeve and our expansion into new clinical areas including Parkinson’s, Cionic is at a critical inflection point. Brooke’s deep commercial expertise will help us bring our technology to more people and accelerate its life-changing impact.”

Harding spent nearly 20 years at Resmed, where she served in senior commercial and strategy roles, most recently as Chief Transformation Officer and previously as General Manager and CEO of Aria Health, a Resmed company. Throughout her career, she has built and scaled high-impact businesses, led global teams across the U.S., Australia, and Asia, and driven measurable growth across regulated healthcare markets.

“I’m thrilled to join Cionic at such an exciting time in the company’s journey,” said Harding. “Cionic’s first-of-its-kind technology is redefining what’s possible for people with mobility challenges, and the team’s deep commitment to both innovation and impact is truly unmatched. We have the opportunity to scale this mission by bringing the Neural Sleeve to more people, and unlock new possibilities for movement for millions.”

Last year Cionic’s second-generation device, the Neural Sleeve 2 received [FDA clearance](#), establishing a new standard in wearable neurotechnology for walking. In the first two months since launch, the Neural Sleeve 2 received a Special Mention in [TIME Magazine’s Best Inventions of 2025](#), and demand for the new device has exceeded expectations, reflecting strong patient and provider enthusiasm. In a continued signal of momentum, the company also started recruitment for a Parkinson’s research study, expanding the conditions addressed by its wearable neurotechnology and advancing its vision of transforming walking for all.

With Harding’s appointment, Cionic continues to strengthen its leadership team and position itself for the next stage of growth. The company is focused on expanding patient access to the

Neural Sleeve, deepening partnerships with clinical rehab institutions, and advancing new applications of its technology to improve mobility and quality of life for people around the world.

For more information, please visit www.cionic.com.

About Cionic

Founded in 2018 and headquartered in San Francisco, Cionic is pioneering the future of walking through an advanced system that combines wearable neurotechnology, adaptive AI, and connected care. With the FDA-cleared Neural Sleeve 2 at its core, Cionic is setting a new standard for mobility care today and building toward a future where people can move further, faster, and fearlessly, across conditions.

Press Contact:

media@cionic.com

772-00430 Rev A - Last Updated 01/8/2026